• Etoposide (VP-16): Optimizing DNA Damage Assays in Cancer Re

  2026-06-13

  Etoposide (VP-16) empowers researchers to dissect DNA double-strand break pathways and apoptosis induction in cancer cells with unmatched specificity. This article provides actionable workflows, troubleshooting guidance, and practical insights rooted in recent mechanistic findings.

• Sorafenib (BAY-43-9006): Applied Workflows in Cancer Biology

  2026-06-12

  Sorafenib (BAY-43-9006) is a benchmark multikinase inhibitor that empowers cancer researchers to dissect angiogenic and proliferative signaling with precision. This article details advanced experimental protocols, troubleshooting insights, and translational guidance—making Sorafenib from APExBIO an indispensable cancer biology research tool.

• SU 5402: Mechanistic Insights & Benchmarks in Cancer Biology

  2026-06-12

  SU 5402 is a selective small molecule inhibitor targeting VEGFR2, FGFR1, and PDGFRβ, widely used in cancer biology and multiple myeloma research. This article details the biochemical rationale, mechanistic action, and critical experimental benchmarks for SU 5402, focusing on its role in cell cycle arrest and apoptosis in FGFR3-dependent models.

• Rapid hiPSC-to-Oligodendrocyte Differentiation via OLIG2 smR

  2026-06-11

  This study pioneers a synthetic modified mRNA (smRNA) approach to efficiently differentiate human-induced pluripotent stem cells (hiPSCs) into functional oligodendrocytes without viral genome integration. The protocol offers a safer, highly efficient alternative for generating oligodendrocyte progenitors, advancing research in cell therapies for neurodegenerative diseases.

• Lovastatin in Translational Research: Mechanism to Applicati

  2026-06-11

  This thought-leadership article explores how Lovastatin, a powerful HMG-CoA reductase inhibitor, is redefining the landscape for translational researchers. By weaving mechanistic insight with experimental strategy and competitive positioning, the discussion highlights opportunities for innovation in cancer, apoptosis, and wound healing research. Drawing on primary literature and best-in-class product guidance, it provides actionable recommendations for maximizing Lovastatin’s impact in advanced biomedical workflows.

• CD44-Mediated Metabolic Rewiring in IDH-Mutant Leukemia

  2026-06-10

  This study identifies CD44-driven metabolic rewiring as a critical dependency in IDH-mutant acute myeloid leukemia (AML). By elucidating the interplay between CD44 expression, NADPH generation, and oncometabolite production, the research highlights new combinatorial therapeutic opportunities and refines our understanding of resistance to IDH2 inhibition.

• Clodronate Liposomes: Precision In Vivo Macrophage Depletion

  2026-06-10

  Clodronate Liposomes empower researchers to selectively deplete macrophages in vivo, enabling causal dissection of immune landscapes in cancer and inflammation. This guide translates breakthrough findings on CCL7+ TAMs into actionable protocols, troubleshooting, and workflow optimization for advanced immunomodulation studies.

• QRICH1 Drives ER Stress-Induced HMGB1 Secretion in HBV Fibro

  2026-06-09

  This study elucidates how QRICH1, a regulator of endoplasmic reticulum (ER) stress, amplifies hepatitis B virus (HBV)-driven HMGB1 translocation and secretion in hepatocytes, thereby promoting liver fibrosis. By dissecting mechanisms involving SIRT6 and HMGB1 transcription, the research highlights new molecular targets for understanding and potentially mitigating HBV-induced hepatic fibrosis.

• Pazopanib Hydrochloride: Multi-Kinase Inhibition in Cancer R

  2026-06-09

  Pazopanib Hydrochloride (GW786034) is a multi-target receptor tyrosine kinase inhibitor used in advanced cancer research. It offers potent suppression of VEGFR, PDGFR, FGFR, and related kinases, enabling robust anti-angiogenic and tumor growth studies. Its well-characterized pharmacology and clinical approvals support its wide application in oncology.

• Lovastatin (SKU A4365): Precision Tools for Cell-Based Assay

  2026-06-08

  This article guides biomedical researchers through practical laboratory scenarios where Lovastatin (SKU A4365) addresses reproducibility, selectivity, and workflow optimization in cell viability, proliferation, and cytotoxicity assays. Drawing on quantitative data and literature, it contrasts APExBIO’s Lovastatin with alternative options and provides actionable advice for protocol design and troubleshooting.

• Curcumol-Induced Autophagy in Hepatic Stellate Cells via Met

  2026-06-08

  This study demonstrates that curcumol induces autophagy-dependent cell death in hepatic stellate cells by disrupting methionine metabolism, implicating a mechanistic link between metabolic flux and antifibrotic effects. Supplementation with S-adenosylmethionine (SAM) partially reverses these effects, highlighting the centrality of methyl donor pathways in liver fibrosis research.

• Bestatin Dissects Jasmonate Signaling via Chemical Genetics

  2026-06-07

  This study establishes bestatin as a precise chemical genetics tool to probe jasmonate (JA) signaling in Arabidopsis. By identifying mutant lines with altered JA responses, the work reveals new loci in plant defense and demonstrates the utility of small molecules in dissecting complex hormone signaling pathways.

• JSH-23: Precision NF-κB Inhibition for Inflammation Research

  2026-06-06

  JSH-23 stands out as a potent, selective NF-κB inhibitor, enabling researchers to dissect inflammatory pathways with high specificity. Its robust performance in both in vitro and in vivo models, especially for NF-κB signaling pathway studies and cytokine inhibition, makes it indispensable for translational inflammation research.

• Linezolid in Translational Research: Mechanisms, Impact, and

  2026-06-05

  This thought-leadership article explores the mechanistic underpinnings and strategic application of Linezolid, a synthetic oxazolidinone antimicrobial, within translational research workflows targeting multi-drug resistant Gram-positive bacteria. Drawing from recent medicinal chemistry advances and benchmarking against emergent anti-tubercular compounds, the discussion offers evidence-backed guidance for experimentalists, highlights APExBIO's product advantages, and positions Linezolid as a pivotal tool in the evolving landscape of antibacterial drug discovery.

• Lopinavir (ABT-378): Advancing HIV Protease Inhibition Workf

  2026-06-05

  Lopinavir (ABT-378) stands out as a potent HIV protease inhibitor, offering robust performance against wild-type and resistant strains—especially in challenging, serum-rich environments. Its proven cross-utility in both HIV and emerging coronavirus research, as illustrated by recent screening studies, makes it indispensable for advanced antiviral workflows.

15292 records 1/1020 page Next 12345 下5页 Last page